ASCO® Annual Meeting 2024

Transforming Precision Medicine: AI and Molecular Insights Intersect Across the Cancer Care Continuum

Discover the rapid evolution of precision oncology with our cutting-edge AI technology and expanded molecular portfolio, now including MRD and monitoring, to enhance the delivery of comprehensive insights to providers and biopharma professionals.

*Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation. Not CME-accredited.

Longitudinal clinical performance of a novel tumor-naive minimal residual disease assay in resected stage II and III colorectal cancer patients: A subset analysis from the GALAXY study in CIRCULATE-Japan Poster Presentation

Relationship Between Dynamic Changes in Circulating Tumor Fraction and Real-World imaging with Real-World Survival in Patients with Solid Tumors Treated with Immunotherapy

TriHealth Cancer Institute’s Collaboration with the Tempus AI TIME Program Impact on Clinical Trial Operations and Enrollment

Comparison of Tumor Immune Microenvironments (TIMEs) Between Primary and Metastatic Sites (Mets) in Triple Negative Breast Cancer (TNBC)

Comparing the Somatic, Germline, and Immune Landscapes of Upper Tract Urothelial Carcinoma (UTUC) and UC of the Bladder (UCB)

Matched Tissue and circulating tumor DNA (ctDNA) Analysis in Renal Cell Carcinoma (RCC): Results from a multimodal real-world database

Cost-effectiveness of a Circulating Tumor Fraction molecular biomarker for treatment response monitoring

Prognostic Value of PORTEC-3 Molecular Markers by Disease Risk in a Real-World Early Endometrial Cancer Cohort

Characterization of DNA damage repair (DDR) alterations and the tumor immune microenvironment (TIME) in advanced non-small cell lung cancer (NSCLC)

Clinicopathologic and molecular landscape of invasive mucinous adenocarcinoma of the lung

EVEREST-1: A seamless phase 1/2 study of A2B530, a CEA logic-gated Tmod CAR T-cell therapy, in patients with NSCLC, CRC, PANC, or other solid tumors associated with CEA expression also exhibiting HLA-A*02 LOH

EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer (PANC), ovarian cancer, mesothelioma, or other solid tumors that show MSLN expression and HLA-A*02 LOH

Improving ethnic and racial diversity in biomarker-driven clinical trials: a proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH)

Quantifying clinical actionability of updated tumor profiling reports through electronic health record (EHR)-enabled, on-demand ordering and resulting

Changes in non-small cell lung cancer (NSCLC) next-generation sequencing (NGS) rates after electronic health record (EHR) integration using large-scale, multi-institutional real-world data

Real-world (rw) treatment (tx) patterns, sequencing, and outcomes in US patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with avelumab first-line maintenance (1LM)

Impact of Exigent Research Network’s Partnership with the Tempus AI TIME Program on the Screening and Matching of Subjects for Clinical Trials

Prognostic impact of BRCA mutation on metastasis-free survival in a localized/locoregional high risk real-world prostate cancer population

Deep learning model on H&E-stained slides predicts whether samples will yield sufficient nucleic acid content for NGS testing